South Korea
· Delayed Price · Currency is KRW CHA Vaccine Research Institute Statistics
Total Valuation
CHA Vaccine Research Institute has a market cap or net worth of KRW 86.61 billion. The enterprise value is 58.09 billion.
| Market Cap | 86.61B |
| Enterprise Value | 58.09B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
CHA Vaccine Research Institute has 26.73 million shares outstanding. The number of shares has increased by 0.35% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 26.73M |
| Shares Change (YoY) | +0.35% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 1.56% |
| Owned by Institutions (%) | 0.06% |
| Float | 15.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 233.48 |
| PB Ratio | 2.66 |
| P/TBV Ratio | 2.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.63 |
| EV / Sales | 156.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.14 |
Financial Position
The company has a current ratio of 60.10, with a Debt / Equity ratio of 0.29.
| Current Ratio | 60.10 |
| Quick Ratio | 48.34 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.49 |
| Interest Coverage | -5.22 |
Financial Efficiency
Return on equity (ROE) is -13.49% and return on invested capital (ROIC) is -9.10%.
| Return on Equity (ROE) | -13.49% |
| Return on Assets (ROA) | -8.16% |
| Return on Capital (ROIC) | -9.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.68% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -42.68% |
| 50-Day Moving Average | 3,689.90 |
| 200-Day Moving Average | 4,419.70 |
| Relative Strength Index (RSI) | 37.78 |
| Average Volume (20 Days) | 55,789 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CHA Vaccine Research Institute had revenue of KRW 370.66 million and -4.26 billion in losses. Loss per share was -159.50.
| Revenue | 370.66M |
| Gross Profit | 346.73M |
| Operating Income | -7.15B |
| Pretax Income | -4.61B |
| Net Income | -4.26B |
| EBITDA | -6.60B |
| EBIT | -7.15B |
| Loss Per Share | -159.50 |
Balance Sheet
The company has 37.99 billion in cash and 9.47 billion in debt, giving a net cash position of 28.53 billion or 1,067.10 per share.
| Cash & Cash Equivalents | 37.99B |
| Total Debt | 9.47B |
| Net Cash | 28.53B |
| Net Cash Per Share | 1,067.10 |
| Equity (Book Value) | 32.69B |
| Book Value Per Share | 1,218.63 |
| Working Capital | 47.70B |
Cash Flow
In the last 12 months, operating cash flow was -6.17 billion and capital expenditures -185.15 million, giving a free cash flow of -6.36 billion.
| Operating Cash Flow | -6.17B |
| Capital Expenditures | -185.15M |
| Free Cash Flow | -6.36B |
| FCF Per Share | -237.77 |
Margins
| Gross Margin | 93.54% |
| Operating Margin | -1,928.25% |
| Pretax Margin | -1,244.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CHA Vaccine Research Institute does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.35% |
| Shareholder Yield | -0.35% |
| Earnings Yield | -4.92% |
| FCF Yield | -7.34% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHA Vaccine Research Institute has an Altman Z-Score of 3.27.
| Altman Z-Score | 3.27 |
| Piotroski F-Score | n/a |